Table 4 Comparison of myelosuppression... | American Society of Hematology

Table 4

Comparison of myelosuppression in patients receiving FCR and alemtuzumab: patients with baseline platelet count less than 10³/μL

	Patient 1	Patient 2	Patient 3	Patient 4
Valaciclovir (N = 4)
Baseline (× 10³/μL)	64	47	99	23
Nadir (× 10³/μL)	22	15	15	9
% change	−66	−68	−85	−61
Toxicity grade*	3	4	4	4
Valganciclovir (N = 4)
Baseline (× 10³/μL)	94	12	81	50
Nadir (× 10³/μL)	40	12	49	6
% change	−57	0	−40	−88
Toxicity grade*	3	4*	2	4

	Patient 1	Patient 2	Patient 3	Patient 4
Valaciclovir (N = 4)
Baseline (× 10³/μL)	64	47	99	23
Nadir (× 10³/μL)	22	15	15	9
% change	−66	−68	−85	−61
Toxicity grade*	3	4	4	4
Valganciclovir (N = 4)
Baseline (× 10³/μL)	94	12	81	50
Nadir (× 10³/μL)	40	12	49	6
% change	−57	0	−40	−88
Toxicity grade*	3	4*	2	4

Platelets < 20 000/μL = grade 4 if baseline > 20 000/μL.